Direct One-Pot Synthesis of Nucleosides from Unprotected or 5-<i>O</i>-Monoprotected <scp>d</scp>-Ribose
作者:A. Michael Downey、Celin Richter、Radek Pohl、Rainer Mahrwald、Michal Hocek
DOI:10.1021/acs.orglett.5b02332
日期:2015.9.18
implications in life and disease. Current synthetic methods involve multistep procedures employing protected sugars in the glycosylation of nucleobases. Using modified Mitsunobu conditions, we report on the firstdirectglycosylation of purine and pyrimidine nucleobases with unprotected d-ribose to provide β-pyranosyl nucleosides and a one-pot strategy to yield β-furanosides from the heterocycle and 5-O-monoprotected
新的,改进的获取核苷的方法不仅对有机化学家而且对整个科学界都普遍感兴趣,因为它们对生命和疾病具有关键意义。当前的合成方法涉及在核碱基的糖基化中采用受保护的糖的多步骤程序。使用改性的Mitsunobu条件下,我们对嘌呤的第一个直接的糖基化报告,并嘧啶核碱基与未受保护的d -核糖提供β-吡喃核苷和一锅策略以产生β-呋喃糖苷从杂环和5- ö -monoprotected d -核糖。
Pentopyranosylnucleoside, its preparation and use
申请人:Nanogen Recognomics GmbH
公开号:US20040198966A1
公开(公告)日:2004-10-07
The invention relates to a pentopyranosylnucleoside of the formula (I) or of the formula (II)
1
their preparation and use for the production of a therapeutic, diagnostic and/or electronic component.
Pentopyranosyl nucleic acid arrays, and uses thereof
申请人:Aventis Research and Technologies GmbH & Co. KG
公开号:US20030039997A1
公开(公告)日:2003-02-27
The invention relates to a pentopyranosylnucleoside of the formula (I) or of the formula (II)
1
their preparation and use for the production of a therapeutic, diagnostic and/or electronic component.
Process for the preparation of a pentopyranosyl conjugate
申请人:Miculka Christian
公开号:US20050053945A1
公开(公告)日:2005-03-10
The invention relates to a pentopyranosylnucleoside of the formula (I) or of the formula (II)
their preparation and use for the production of a therapeutic, diagnostic and/or electronic component.
本发明涉及公式(I)或公式(II)的五碳杂环核苷的制备及其用于制备治疗、诊断和/或电子组件。
PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE
申请人:Miculka Christian
公开号:US20090221793A1
公开(公告)日:2009-09-03
The invention relates to a process for preparing a conjugate that includes a pentopyranosyl nucleic acid and a biomolecule. The process includes the steps of providing a pentopyranosyl nucleic acid having at least two pentopyranosyl nucleotide subunits that are covalently linked between carbon 4 and carbon 2 of their respective pentopyranosyl rings. The pentopyranosyl nucleic acid also has an electrophilic reactive group. A biomolecule having a nucleophilic reactive group is also provided. The electrophilic reactive group of the pentopyranosyl nucleic acid and the nucleophilic reactive group of the biomolecule are reacted to form a covalent bond.